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Abstract 
Aim 
The unfolded protein response (UPR) is a pro-survival defense mechanism induced during periods 
of endoplasmic reticulum stress, and it has recently emerged as an attractive therapeutic target 
across a number of neurodegenerative conditions, but has not yet been studied in synuclein 
disorders.  
Methods 
The level of a key mediator of the UPR pathway, glucose regulated protein 78 (GRP78), also 
known as binding immunoglobulin protein (BiP), was measured in post-mortem brain tissue of 
patients with dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) in 
comparison to Alzheimer’s disease (AD) and age matched controls using western blot. The UPR 
activation was further confirmed by immunohistochemical detection of GRP78/BiP and 
phosphorylated protein kinase RNA-like ER kinase (p-PERK). 
Results 
GRP78/BiP was increased to a greater extent in DLB and PDD patients compared to AD and 
control subjects in cingulate gyrus and parietal cortex. However, there were no changes in the 
prefrontal and temporal cortices. There was a significant positive correlation between GRP78/BiP 
level and -synuclein pathology in the cingulate gyrus, while AD-type pathology showed an 
inverse correlation relationship in the parietal cortex.  
Conclusion 
Overall, these results give emphasis to the role of UPR in Lewy body dementias, and suggest that 
Lewy body degeneration, in combination with AD-type pathologies, is associated with increased 
UPR activation to a greater extent than AD alone, possibly as a consequence of the increasing load 
of ER proteins. This work also highlights a novel opportunity to explore the UPR as a therapeutic 
target in synuclein diseases. 
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List of Abbreviations 
 
Abbreviation Full name 
AD Alzheimer’s disease 
ATF6 Activating transcription factor 6 
A Amyloid- 
BA Brodmann area 
BiP Binding immunoglobulin protein 
CERAD Consortium to Establish a Registry for Alzheimer’s Disease 
DLB Dementia with Lewy bodies 
ER Endoplasmic reticulum 
GRP78 Glucose regulated protein 78 
IRE1 Inositol-requiring enzyme 1 
MMSE Mini-Mental State Examination 
NIA-AA National Institute on Aging - Alzheimer’s Association 
p-PERK Phosphorylated protein kinase RNA-like ER kinase 
PDD Parkinson’s disease dementia 
PERK Protein kinase RNA-like ER kinase 
UPR Unfolded protein response 
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Introduction 
Dementia with Lewy-bodies (DLB) is a common, but clinically under-recognised 
neurodegenerative disease. The clinical presentation is complex with more impact on quality of life 
and carer-burden and higher health-related costs compared to Alzheimer’s disease (AD), and also 
with a shorter survival [1, 2]. There is a need for better mechanistic understanding of DLB to drive 
development of improved disease modifying treatments. 
Accumulation of disease-specific misfolded proteins in the brain and subsequent neuronal loss 
is a key mechanism across a number of neurodegenerative diseases. Although a great deal of effort 
has been made to unravel how each individual ‘toxic’ protein exerts its deleterious effects in 
specific disorders, mechanistic understanding of how these proteins cause neuronal loss has been 
limited and thus the development of disease modifying treatments for neurodegenerative diseases 
has remained as a challenge.  
Endoplasmic reticulum (ER) stress is another common theme in these diseases. The ER 
controls many of the cellular processes, and disturbance in ER function, usually caused by 
accumulation of unfolded proteins and calcium homeostasis within the ER, leads to ER stress. 
Although the sub-cellular loci of protein misfolding can vary between diseases, the interdependence 
of protein folding throughout the cell implies that ER dysfunction/stress could be the final common 
pathway for numerous neurodegenerative diseases [3]. It is well known that upon ER stress, cells 
activate a series of complementary adaptive mechanisms to deal with protein-folding alterations, 
which together are known as the unfolded protein response (UPR). The UPR increases overall 
protein-folding capacity, in addition to enhancing the efficiency of quality control and protein 
degradation mechanisms to reduce the unfolded protein load [4]. Most cell types are relatively 
resistant to the accumulation of misfolded protein through continuous dilution of the ER by cell 
replication, but this procedure is unavailable to post-mitotic neurons, therefore neurons depend 
totally on the UPR for survival of such insult [5].  
The UPR orchestrates adaptation to protein folding stress by modulating at least three parallel A
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signalling pathways, initiated by the activation of the stress sensors: protein kinase RNA-like ER 
kinase (PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6). In 
resting cells, PERK, IRE1, and ATF6 are associated with an ER chaperone, GRP78/BiP, which 
keeps them inactive. However, under conditions of ER stress, in order to deal with the increasing 
load of ER proteins, GRP78/BiP dissociates from these three proteins leading to their activation. 
UPR acts as a protective mechanism against the accumulation of toxic misfolded proteins which 
combines the early inhibition of protein synthesis with a later up-regulation of genes that promote 
protein folding or disposal to equilibrate disturbed ER homeostasis. Both of these translational and 
transcriptional elements of the UPR protect neurons from being overwhelmed by misfolded ER 
proteins. [3, 5]. However, under chronic or irreversible stress conditions, the UPR shifts its 
signalling toward cell death mechanisms by activating complex pro-apoptotic programmes [6]. 
Elucidating the role of UPR in the regulation of protein homeostasis begun almost three 
decades ago when Kozutsumi and colleagues showed that the presence of misfolded proteins in the 
ER signals the induction of GRP78 and GRP94 in simian cells [7]. A few years later, the first 
indication that the ER stress mechanism was involved in neurodegenerative diseases came from 
Hamos and colleagues, in which the level of GRP78/BiP was increased in the cytologically normal 
hippocampal neurons of the AD patients [8]. Since then, the number of studies investigating the role 
of UPR in various neurodegenerative diseases including PD and AD has grown exponentially [9-
13]. Furthermore, manipulation of the UPR via genetic methods in animal models has also 
demonstrated that UPR activation can directly contribute to neurodegeneration [14]. Interestingly, it 
was shown that dysregulation of protein synthesis may play an essential role in neurodegenerative 
diseases by directly affecting the expression of synaptic proteins, leading to synaptic dysfunction 
and neuronal loss [15]. Recently, Moreno et al. took these findings a step further and showed that 
inhibiting a key mediator of the UPR pathway by a specific PERK inhibitor prevented UPR-
mediated translational repression and abrogated development of clinical signs of prion disease in 
mice, with neuroprotection throughout the mouse brain [16]. Furthermore, Ma and colleagues A
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reported that conditional deletion of PERK in an APP/PS1 transgenic mouse model of AD recued 
synaptic protein expression and ameliorated synaptic dysfunction [17]. Together, these studies 
reveal that failure to restore protein homeostasis and prolonged UPR activation may be neurotoxic 
rather than neuroprotective, and point to a new way of treating neurodegenerative diseases. 
Until now, several studies have shown promising results for UPR as a potential therapeutic 
target for AD and PD, but there are gaps in the knowledge regarding the involvement of UPR in 
cases of dementia where both AD and PD pathology are evident, such as PD with dementia (PDD) 
and DLB. The pathological hallmarks of PDD and DLB are accumulation of Lewy bodies and 
Lewy neurites, principally composed of -synuclein [18-21]. Although these are defining 
abnormalities for PDD and DLB, approximately 40% of cases have additional amyloid- (A) and 
neurofibrillary tangle pathology [22, 23], with more pronounced cognitive dysfunction than in 
patients with ‘pure’ AD [24, 25]. Therefore, the aim of the present study is to investigate whether 
the UPR pathway is activated to a greater extent with co-occurrence of tau and -synuclein 
pathology, in PDD and DLB, in comparison to AD and control subjects, and whether the UPR 
activity is associated with clinical and/or pathological measures. 
 
Materials and methods 
Post-mortem human brain tissue 
Post-mortem brain tissue was obtained from several sources; University Hospital Stavanger 
(Norway), the MRC London Neurodegenerative Diseases Brain Bank, the Thomas Willis Brain 
Collection and the Newcastle Brain Tissue Resource. The UK brain banks are part of the Brains for 
Dementia Research Network. All participants gave informed consent for their tissue to be used in 
research and the study had ethics approval from the UK National Research Ethics Service 
(08/H1010/4 and KI IRB) and from the Ethics Review Board of Sweden (etikprövningsnämnderna, 
2013/914-31/4) . The demographic details of the patients and control subjects are shown in Table 1. 
Biochemical and histopathological analysis was undertaken on prefrontal cortex (Brodmann area A
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(BA) 9; n = 99), temporal cortex (BA21; n = 93), anterior cingulate gyrus (BA24; n = 89) and 
parietal cortex (BA40; n = 118). Only prefrontal cortex tissue sections were available for 
immunohistochemical analysis and temporal cortex tissues from AD patients were not available due 
to technical reasons. 
Neuropathological assessment and diagnosis was performed according to standardised 
neuropathological scoring/grading systems, including Braak staging, Consortium to Establish a 
Registry for Alzheimer’s Disease (CERAD) scores, Newcastle/McKeith Criteria for Lewy body 
disease, National Institute on Aging - Alzheimer’s Association (NIA-AA) guidelines for Aβ 
deposition, neurofibrillary tangle, and Lewy body and neurite pathologies [26-30]. For each region, 
semi-quantitative assessments for each of the three pathologies were conducted, ranging from 0 
(none), 1 (sparse), 2 (moderate) to 3 (severe) as previously described [31]. Controls were 
neurologically normal, with only mild age associated neuropathological changes (e.g., 
neurofibrillary tangle Braak stage ≤II) and no history of neurological or psychiatric disease. 
Cognitive impairment data consisted of the last Mini-Mental State Examination (MMSE) scores a 
maximum of two years prior to death. Most patients were longitudinally followed (usually over 8-
10 years) and annual rate of decline on MMSE was calculated. Final diagnoses for patients are 
clinico-pathological consensus diagnoses incorporating the one-year rule to differentiate DLB and 
PDD [27]. Hoehn & Yahr scores were also taken from the subset of PDD patients. 
 
Immunohistochemistry 
Immunolabelling of sections was undertaken as previously reported [32, 33]. Briefly, 7 m sections 
from cingulate gyrus, prefrontal and parietal cortices were dewaxed and rehydrated through xylene 
and descending concentrations of alcohol into water. For GRP78/BiP and phosphorylated tau, 
antigen retrieval was carried out by microwaving for 10 minutes in citrate buffer pH6.0. For PERK, 
pPERK, and -synuclein, antigen retrieval was carried out by autoclaving for 10 minutes in EDTA 
buffer pH8.0; this was followed by immersion for 15 minutes in 98% formic acid for -synuclein 
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(only). For immunohistochemistry, endogenous peroxidases were blocked by 0.3% hydrogen 
peroxide in PBS (30 minutes). Primary antibodies were added (PERK 1:1500 Abcam ab115617; 
pPERK 1: 200 Santa Cruz sc32577; BiP 1:1000 Abcam ab21685;phosphorylated tau AT8 1:200 
Thermo Scientific MN1020; -synuclein, NCL-  N       Novacastra Laboratories) and tissue 
sections incubated overnight at    C.  Subsequent labelling for light microscopy involved 
appropriate biotinylated secondary antibodies (all at 1:500 Vector Labs, Peterborough, UK), ABC 
Elite and DAB kits (Vector Labs). Counter staining was with Mayer’s haematoxylin ( igma). When 
sections were double labelled, the second chromogen was Novared (Vector Labs).  
 
Western Blotting 
Western blot was performed as previously described [32, 33]. Briefly, 500mg of frozen tissue was 
taken from each brain region. Meninges, white matter, blood vessels and clots were dissected from 
the frozen tissue to leave approximately 200mg of grey matter which was homogenised in ice cold 
buffer (pH 7.4) containing 50mM tris-HCL, 5mM EGTA,   mM EDTA, ‘complete protease 
inhibitor cocktail tablets’ (Roche), and 2μg/ml pepstatin A dissolved in ethanol:DMSO 2:1 (Sigma). 
Buffer was used at a ratio of 2ml to every 100mg of tissue and homogenisation performed using an 
IKA Ultra-Turrax mechanical probe (IKA Werke, Germany) until the liquid appeared homogenous. 
Protein concentration of each sample was measured by using BCA Protein Assay Kit (Thermo 
Scientific). 
Twenty micrograms of each sample was loaded on 7.5% SDS-polyacrylamide gel for protein 
separation then transferred to nitrocellulose membrane (Immobilon-P, Millipore). After blocking 
non-specific binding, the membranes were incubated with anti-GRP78/BiP (rabbit polyclonal, 
1:1000, Abcam) primary antibody followed by an anti-rabbit HRP conjugated secondary antibody 
(GE healthcare, 1:5000). Bands were visualised using chemiluminescent substrate (Millipore) and a 
LAS-3000 luminescent image reader (Fujifilm). Western blot data were evaluated and quantified 
using Multi Gauge Image Analyzer (version 3.0). In order to control for any inconsistency in A
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loading samples, ‘house-keeping’ proteins were used as internal controls to check whether the 
differences in the amount of protein of interest could be due to an initial difference in the amount of 
sample loaded. The most commonly used protein to serve this purpose is -actin, as actin is a 
cytoskeletal filament that forms the internal scaffolding of a cell, and therefore its expression is 
ubiquitous in neuronal and non-neuronal tissue [34]. Each membrane was therefore probed for actin 
(1:10000 dilution, Sigma-Aldrich) to normalise the level of immunolabelling of the GRP78/BiP 
protein to actin, so that any potential variations in protein loading could be eliminated. 
 
Statistical analysis 
Statistical analyses were performed using SPSS. Shapiro-Wilk and Levene’s tests were used to 
ensure that the parametric assumptions of normality and homogeneity of variance respectively, 
were not violated. Where assumptions were found to be violated, a natural log (Ln) data 
transformation was applied and the data were retested for normality and equal variance [35]. One-
way ANOVA followed by Scheffe post-hoc test was performed where data could be normalised, 
otherwise Kruskal-Wallis non-parametric analysis was performed. Spearman correlation analyses 
were used to determine the association between the level of GRP78/BiP protein and clinical and 
pathological measures. 
 
Results 
There were no significant associations between age and GRP78/BiP protein levels in any of the four 
regions (r between -0.15 and 0.18, P > 0.2 for all regions). However, there was a significant 
difference in the average age of death between diagnostic groups (One-way ANOVA, F(3,126) = 
6.044, P = 0.001), in which AD patients had significantly higher average age of death compared to 
control subjects (P = 0.003) or patients with DLB (P = 0.016) or PDD (P = 0.002). There were no 
significant differences in gender, pH, MMSE, or annual rate of MMSE decline between diagnostic 
groups (Table 1).  A
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Protein levels of GRP78/BiP are increased in cingulate gyrus and parietal cortex of PDD and DLB 
patients 
In the cingulate gyrus, there was a significant increase in the level of GRP78/BiP in PDD and DLB 
patients compared to AD and control subjects (P < 0.001, Figure 1A, E). A similar pattern was 
observed in the parietal cortex, in which the GRP78/BiP level in the PDD and DLB patients were 
significantly higher compared to AD patients (P = 0.002 for PDD; P = 0.001 for DLB, Figure 1B). 
Interestingly, there was a significant decrease in the GRP78/BiP level in AD patients compared to 
control subjects in parietal cortex (P < 0.001, Figure 1B). There were no significant changes in the 
level of GRP78/BiP between different disease groups in either prefrontal (Figure 1C), or temporal 
cortices (Figure 1D).  
 
Localisation of GRP78/BiP, PERK, p-PERK, and -synuclein in neurons in the prefrontal cortex 
The prefrontal cortex was selected for immunohistochemical analysis as this region is proposed to 
have a role in executive function and cognition, a deterioration of which is a cardinal symptom of 
DLB and PDD. The GRP78/BiP localised in the cytoplasm of neurons (Figure 2). Although there 
was a slight increase in the labeling intensity of GRP78/BiP in AD, PDD, and DLB patient samples 
compared to normal control, this intensity was similar across the different disease groups (Figure 2). 
Since there were changes in the GRP78/BiP levels in the cingulate gyrus and parietal cortex region, 
GRP78/BiP labelling was also done in these areas (Supplementary material, Figure S1). The 
number of GRP78/BiP-positive cells in AD, PDD, and DLB patients appeared to be slightly greater 
than control subjects, but again was similar across the different disease groups in both brain regions. 
In both PDD and DLB patient samples, GRP78/BiP was co-localised with -synuclein only in some 
of the neurons (arrows, Figures 3A–D). In AD patient samples, GRP78/BiP-positive neurons were 
seldom co-localised with phosphorylated Tau (green arrow, Figure 3E), and majority of the 
GRP78/BiP-positive neurons had no phosphorylated Tau (blue arrow, Figure 3E, F). Furthermore, A
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phosphorylated Tau-positive neurofibrillary tangles did not show GRP78/BiP immunoreactivity 
(arrowhead, Figure 3F). Similarly, in DLB patient samples, there were no apparent neurons 
expressing both the GRP78/BiP and phosphorylated Tau (arrow, Figure 3G, H), and neurofibrillary 
tangles had no GRP78/BiP expression either (arrowhead, Figure 3G, H). Granular staining was 
observed for p-PERK in AD, PDD, and DLB patient samples (Figures 4B–D), in which the 
intensity appeared to be a little higher in the PDD and DLB patients compared to AD patients 
(Figure 4B). The staining intensity of p-PERK was higher in all cases compared to controls (Figure 
4A). PERK and p-PERK staining on sequential sections showed that a greater number of neurons 
were positive for PERK (arrows, Figure 4E) than p-PERK (arrows, Figure 4F). 
 
Association between GRP78/BiP level and clinical and pathological measures 
The average regional pathological scores for each disease group are presented in Table 2, and the 
association between GRP78/BiP level and pathological measures are shown in Table 3. There was a 
significant positive correlation between GRP78/BiP level and -synuclein in the cingulate gyrus (R 
= 0.629, P < 0.001), and inverse correlation with plaques and tangles in the parietal cortex (R = -
0.364 and -0.301 respectively, P < 0.001 for both) (Table 3). However, there were no significant 
associations between the GRP78/BiP level and both Braak stages and Newcastle/McKeith criteria 
for Lewy body disease, MMSE scores before death or annual rate of MMSE decline in all patients 
in each disease group (data not shown). Hoehn & Yahr scores of a subset of PDD patients (n = 22) 
also showed no correlation with GRP78/BiP level (data not shown). 
 
Discussion 
The present study is the first study to report UPR activation in PDD and DLB. The novel finding of 
the current study is that the level of GRP78/BiP was greatly increased in the PDD and DLB patients 
compared to people with AD in cingulate gyrus (Figure 1A) and parietal cortex (Figure 1B), 
suggesting that the UPR pathway may be activated to a greater extent in cases with cortical Lewy A
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body pathology or where both Lewy body and plaque pathologies are present. In the cingulate gyrus, 
GRP78/BiP level in PDD and DLB patients were also significantly higher compared to controls 
(Figure 1A). However, the level of GRP78/BiP did not change in the prefrontal or temporal cortices 
of all disease groups (Figures 1C, D), which may imply that the UPR is activated at a different level 
in different areas of the brain depending on the severity of the pathology in that particular region at 
the time of death. 
In the cellular and animal models of PD, an increase in the proteins that are involved in the 
UPR pathway such as GRP78/BiP and PERK has been shown, suggesting UPR activation and the 
involvement of ER stress in the pathophysiology of the disease [12, 36, 37]. Similar results were 
observed in human post-mortem tissue from PD patients [9, 38]. However, there have been 
discrepancies in the level of GRP78/BiP in AD patients. In some of the studies, it was reported that 
the expression level of GRP78/BiP is increased [8, 10, 39], whereas in other studies either a 
decrease or no changes at all between control subjects and AD patients were reported [40, 41]. 
These differences may be explained by the use of different antibodies (a generic anti-KDEL 
antibody versus GRP78/BiP specific antibody) or stages of the disease, or different regions studied. 
Consistent with aforementioned studies, the present study has also shown varying results in 
different brain areas, in which the level of GRP78/BiP in AD patients did not change in cingulate 
gyrus or in prefrontal cortex, but was significantly decreased in the parietal cortex (Figure 1). A 
decrease in the GRP78/BiP level in AD patients in the parietal cortex may not be due to their 
significantly higher age compared to other disease groups, but could be the result of pathological 
differences between AD and Lewy body diseases such as DLB and PDD. It has been shown that 
prominent atrophy and degenerative changes occur in the parietal cortex region in AD [42-44]. 
Therefore, it can be hypothesised that the decrease in the GRP78/BiP in parietal cortex in AD 
patients may be due to the absence of and/or limited number of “healthy” cells present in this region 
to activate the UPR pathway. This attenuated UPR signalling may in turn exacerbate atrophy and A
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neurodegeneration by increasing vulnerability to ER stress in which a cell is forced to take the 
apoptotic route without having any chance to repair itself. 
GRP78/BiP immunohistochemical results from the current study were also consistent with 
previous studies [8, 10], in which GRP78/BiP was localised in the neuronal cytoplasm, and the 
labeling intensity was slightly higher in the AD, PDD, and DLB patients compared to control 
subjects (Figure 2). Furthermore, in AD patients, only a very few GRP78/BiP-positive neurons 
expressed phosphorylated Tau (Figure 3E), and neurofibrillary tangles did not show GRP78/BiP 
immunoreactivity (Figure 3F). As described previously [10, 39], p-PERK immunoreactivity was 
observed as granules in the cytoplasm of neurons in the prefrontal cortex (Figure 4B–D). More 
neurons were positive for PERK than p-PERK (Figure 4E, F), which may suggest that the majority 
of neurons are primed for UPR activation, but only some of them actually become activated.  
Although the present study investigated the regions with known pathological involvement 
for AD, PDD, and DLB, small sample size and analysis of only four cortical regions may have been 
limitations to finding greater changes in the GRP78/BiP level. Furthermore, there may be larger 
group differences in GRP78/BiP level with other quantitative approach looking at protein 
distribution and expression at cellular level as opposed to analysing proteins in tissue homogenates 
by western blotting. Finally, the correlation analysis between the age and GRP78/BiP level was 
carried out to determine whether the age was a confounding factor. This analysis was conducted 
regardless of the diagnostic groups. Although there was no association between the GRP78/BiP 
level and age (data not shown), the fact that the age may have influenced the comparison between 
AD and other groups cannot be totally excluded as AD patients were significantly older in age at 
the time of death (Table 1). The DLB and PDD patients were well age-matched to the control group.  
While the UPR is normally a neuroprotective response, it seems that chronic activation, and 
the conversion of cytoprotective to cytotoxic signaling may be the contributing factors to disease. 
Greater increase in GRP78/BiP level in PDD and DLB compared to AD observed in the current 
study suggests that UPR may be activated at a greater degree because both -synuclein and A A
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pathology are present in PDD and DLB. In other words, in patients with PDD or DLB, there may be 
a greater build-up of misfolded ‘toxic’ protein in the ER compared to ‘pure’ AD patients due to co-
occurrence of synuclein and Apathologies. Therefore, as a consequence, the UPR may become 
activated at a higher degree to cope with a greater level of disturbance in proteostasis. On the other 
hand, it was interesting that only synuclein pathology was positively correlated with GRP78/BiP 
level in the cingulate gyrus (Table 3), which coincides well with the increase in GRP78/BiP level in 
the same region only in PDD and DLB patient groups, but not in AD compared to control (Figure 
 A). The α-synuclein influence on the level of GRP78/BiP in the cingulate gyrus may be related to 
the fact that this is the region with highest α-synuclein pathology (Table 2). There may be an effect 
in other areas also, but this may not be evident in the samples due to less severe pathology. This 
suggests that the Lewy body pathology in itself may be sufficient to chronically activate the UPR 
system. A decrease in GRP78/BiP level only in AD patients in the parietal cortex (Figure 1B) and 
inverse correlation between AD-type pathology (plaques and tangles) and GRP78/BiP level in the 
same region (Table 3) further indicate that the AD-type pathology alone may not activate the UPR 
system as much. Therefore, this co-occurrence of synuclein pathology with AD-type pathology may 
be a trigger to change cytoprotective properties of the UPR system to cytotoxic. There has been 
ongoing debate as to whether it is -synuclein pathology or AD-type pathology that drives 
cognitive decline in DLB, and emerging evidence suggests that there may be a synergism between 
-synuclein, amyloid and tau pathologies [45]. The data from the present study are also in line with 
this, and suggest that activated UPR and subsequent protein misfolding is a common mechanism 
leading to these changes, and may particularly be important amongst individuals with cortical Lewy 
bodies or a combination of pathologies.  
However, since the current study only measured the changes in the GRP78/BiP level, there 
are still some unresolved questions before any firm conclusions can be made. For example, does 
higher GRP78/BiP level suggest chronic UPR activation or does it simply suggest transient higher 
UPR activation? If the disease-specific toxic proteins are prevented from building up in the ER A
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lumen, will UPR still be activated? Is UPR activation a response to neurodegeneration or does it 
contribute to disease initiation? To answer these questions further studies are inevitable. However, 
the results from the present study serve as a stepping stone for future studies as this study has 
clearly shown that the UPR is involved in Lewy body dementias for the first time. In addition, now 
that the UPR is emerging as a promising therapeutic target for neurodegenerative diseases [15, 16, 
46], further studies, possibly using cellular or animal models of Lewy body dementia, are required 
to investigate whether the detrimental effect of neurodegeneration can be saved by manipulating the 
UPR pathway. Based on previous studies, using compounds to inhibit UPR appears to be a viable 
therapy [16, 37, 47]. Another important implication to take from the present study is that since UPR 
is activated at a different level in patients with both -synuclein and tau pathology (PDD and DLB 
patients) compared to patients with single pathology (AD patients), it is possible that there may be 
specific mechanisms acting in people with both pathologies. This may become an important fact to 
bear in mind when selecting samples for further investigations, evolving diagnostic criteria, and 
stratifying populations for clinical trials. 
On the whole, the results from the current study highlight the role of UPR in Lewy body 
dementias, and suggest that Lewy body disease and the combination of Lewy body and AD-type 
plaque pathologies are associated with increased UPR activation to a greater extent than it is in pure 
AD, possibly as a consequence of the increasing load of ER proteins. This work highlights a novel 
opportunity to explore the UPR as a therapeutic target in synuclein diseases. 
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Figure legends 
Figure 1. GRP78/BiP protein expression levels in various regions of the brain from healthy control, 
AD, PDD, and DLB subjects. (A) In cingulate gyrus (BA 24) region, there was a significant 
increase in the level of GRP78/BiP protein in PDD and DLB patients compared to AD and control 
subjects. (B) In parietal cortex (BA 40) region, there was a significant decrease in the level of 
GRP78/BiP protein in AD patients compared to control subjects, while its level was significantly 
higher in the PDD and DLB patients compared to AD patients. (C, D) There were no significant 
changes in the GRP78/BiP protein level in prefrontal cortex (BA 9) (C) or temporal cortex (BA 21) 
(D) regions. (E) A representative western blot image showing GRP78/BiP protein expression in 
cingulate gyrus region in control, AD, PDD, and DLB subjects. * P = 0.002, ** P = 0.001, *** P < 
0.001.  
 
Figure 2. Immunohistochemical detection of GRP78/BiP in prefrontal cortex region (BA 9) of 
control (A), AD (B), PDD (C), and DLB (D) subjects. GRP78/BiP protein expression was found in 
the cytoplasm of neurons (arrows). Although there was a slight increase in the labelling intensity in 
AD, PDD, and DLB patient samples compared to healthy control, this intensity was more or less 
similar amongst different disease groups. Scale bars represent 25 m. 
 
Figure 3. Double immunohistochemical labeling of GRP78/BiP with either -synuclein or 
phosphorylated Tau in prefrontal cortex region (BA 9) of various neurodegenerative diseases. (A–
D) In both PDD and DLB patient samples, only a few neurons expressed both GRP78/BiP and a-
synuclein (arrows). Majority of neurons only expressed GRP78/BiP in the cytoplasm (arrowheads). 
(E–H) In AD (E, F) and DLB (G, H) patient samples, GRP78/BiP was rarely co-localised with 
phosphorylated Tau (green arrow), while most of neurons only expressed GRP78/BiP in the 
cytoplasm (blue arrow). Neurofibrillary tangles did not show any immunoreactivity against 
GRP78/BiP (arrowheads). A
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Figure 4. Immunohistochemical expression of p-PERK in prefrontal cortex (BA 9) region of control 
(A), AD (B), DLB (C), and PDD (D) subjects. (A–D) Granular staining pattern was observed in the 
cytoplasm of a neuron in all cases. The labeling intensity appeared to be greater in the AD, PDD, 
and DLB patient samples compared to control. (E, F) As can be seen from the adjacent sections 
from DLB patient samples, a greater number of neurons express PERK (E) than p-PERK (F). 
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Tables 
Table 1. Demographic characteristics of subjects used in this study in each diagnostic group.  
Diagnosis 
Gender (M/F) 
(%) 
Age at death pH 
MMSE before 
death 
MMSE decline 
per year 
Control (n = 25) 60/40 79.8 + 1.5 6.47 + 0.06 N/A N/A 
AD (n = 16) 31/69 88.0 + 2.0 6.30 + 0.08 10.5 (0-19) 3.8 + 1.0 
PDD (n = 34) 53/47 79.9 + 1.0 6.44 + 0.06 13 (0-27) 2.0 + 0.3 
DLB (n = 55) 58/42 81.7 + 0.9 6.37 + 0.06 14 (0-30) 3.0 + 0.4 
 
“MM E before death” is the score at the last interview before death. “MM E decline” is the decline per year averaged 
over the period of clinical observation and was usually 8–10 years. No MMSE data were available for control group. 
MMSE is presented with a median score with range in brackets. Other measures are presented as mean + SEM. 
 
Table 2. Average regional pathological scores for each disease group 
Brain region Diagnosis N -Synuclein Plaques Tangles 
Prefrontal cortex 
(BA 9) 
Control 14–16 -- 0.35 + 0.14 0.17 + 0.08 
AD 11 0.13 + 0.09 2.81 + 0.14 2.56 + 0.13 
PDD 26–28 0.79 + 0.14 1.39 + 0.20 0.53 + 0.10 
DLB 41–44 1.62 + 0.15 1.68 + 0.15 0.93 + 0.11 
Temporal cortex 
(BA21) 
Control 16–25 -- 0.57 + 0.18 0.30 + 0.15 
PDD 30-33 0.94 + 0.15 0.74 + 0.10 0.44 + 0.11 
DLB 34–35 1.75 + 0.15 1.73 + 0.14 1.31 + 0.13 
Cingulate gyrus 
(BA 24) 
Control 20 -- 0.29 + 0.17 0.10 + 0.07 
AD 15–16 0.31 + 0.18 1.47 + 0.27 1.44 + 0.32 
PDD 10 1.85 + 0.18 0.97 + 0.17 0.53 + 0.11 
DLB 36–40 2.28 + 0.13 1.28 + 0.15 1.23 + 0.14 
Parietal cortex 
(BA 40) 
Control 18–23 -- 0.39 + 0.16 0.04 + 0.04 
AD 15 0.13 + 0.09 2.63 + 0.18 2.81 + 0.10 
PDD 29–33 0.59 + 0.13 1.23 + 0.19 0.48 + 0.10 
DLB 46–47 1.39 + 0.13 1.47 + 0.15 0.98 + 0.12 
 
Pathology scores ranged from 0 (none), 1 (sparse), 2 (moderate) to 3 (severe). Pathology scores for -Synuclein in the 
control group were not available for all brain regions. Values are presented as mean + SEM. 
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Table 3. Correlations between GRP78/BiP level and pathology scores in different brain regions. 
Brain region N -Synuclein Plaques Tangles 
Prefrontal cortex 
(BA 9) 
92–95 -0.009 0.094 -0.017 
Temporal cortex 
(BA21) 
80–91 -0.091 0.031 -0.107 
Cingulate gyrus 
(BA 24) 
81–85 0.629 0.163 0.154 
Parietal cortex 
(BA 40) 
108–115 0.010 -0.364 -0.301 
 
Values are Rs and those in red indicate statistically significant correlations (P < 0.001) between that variable and 
GRP78/BiP level. 
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